

Lesotho

Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Lesotho						
2. Vaccine grant number:	08-LSO-08b-Y, 1215-LSO-04A-X, 1215-LSO-04c-X, 1617-LSO-04c-X, 18-LSO-04c-X, 1922-LSO-04c-X, LSO-Lumpsum-1						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	30 November 2012						
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine						
6. Vaccine type:	DTP-HepB-Hib						
7. Requested product presentation and formulation of vaccine:	Penta, 10 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2003-2022						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2003-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	2,818,146	20,000	71,000	69,500	-	-	2,978,646
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2008	08-LSO-08b-Y					100,000
	Disbursement						
	Disbursement date						Amount (US\$)
	05 February, 2008						100,000
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	Type of supplies to be purchased with Gavi funds	2003-2019					2020
	Number of vaccine doses						27,400

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	2,818,146	20,000
-----------------------	-----------	--------

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022
Number of vaccine doses	3,000	12,500	14,500
Number of AD syringes	2,800	11,600	13,300
Number of re-constitution syringes	-	-	-
Number of safety boxes	50	150	150
Value of vaccine doses (US\$)	2,070	8,661	9,962
Total co-financing payments (US\$) (including freight)	2,500	9,500	11,000

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019